Kynam Capital Management »

Alnylam Pharmaceuticals shares owned by Kynam Capital Management

Quarter-by-quarter ownership of Alnylam Pharmaceuticals (ALNY) shares owned by Kynam Capital Management from 13F filings

Historical chart of Kynam Capital Management investment in Alnylam Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Alnylam Pharmaceuticals held by Kynam Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alnylam Pharmaceuticals by Kynam Capital Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $10M 43k 243.00
2022-06-30 $925k 50k 18.50

More positions owned by Kynam Capital Management

Natera (NTRA)
Vertex Pharmaceuticals Incorporated Put Option (VRTX)
Celldex Therapeutics Com New (CLDX)
Syndax Pharmaceuticals (SNDX)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Dynavax Technologies Corp Com New (DVAX)
Cogent Biosciences (COGT)
Insmed Com Par $.01 Call Option (INSM)
Vaxcyte (PCVX)
Vera Therapeutics Cl A (VERA)
BioCryst Pharmaceuticals (BCRX)
Protagonist Therapeutics (PTGX)
2seventy Bio Common Stock (TSVT)
Miragen Therapeutics (VRDN)
Wave Life Sciences SHS (WVE)

View all positions for Kynam Capital Management

Top funds holding Alnylam Pharmaceuticals

Capital World Investors
Vanguard Group
BlackRock
BlackRock
Capital Research Global Investors
Baillie Gifford & Co
Capital Research and Management Company - Division 3
Dodge & Cox
State Street Corporation
T. Rowe Price Associates
T. Rowe Price Investment Management
Jpmorgan Chase & Co
Geode Capital Management
American Century Companies
Groupama Asset Managment

View all funds holding Alnylam Pharmaceuticals